BDX (Becton Dickinson) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDX Becton Dickinson & Co BDX
79 GF Score
Price $166.34
GF Value $188.07
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Becton Dickinson Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

BDX
79GF Score
Becton Dickinson & Co BDX
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Becton Dickinson (BDX) Overvalued in 2026?

Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued. The current stock price of $166.34 is trading 11.6% below its estimated GF Value™ of $188.07. GuruFocus considers Becton Dickinson to be Modestly Undervalued.

Key valuation signals for BDX:

  • Total Noninterest Expense:
  • GF Value™: $188.07 vs. price of $166.34 (11.6% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Becton Dickinson Business Description

Address 1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
79GF Score

Get the complete analysis for BDX

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$166.34
Price
$188.07
GF Value